Lymphoma

Source: www.ncbi.nlm.nih.gov --- 19 days ago
Related Articles Primary breast Lymphoma: case reports and review of the literature. G Chir. 2008 May;29(5):230-2 Authors: Sanguinetti A, Ragusa M, Lucchini R, Monacelli M, Calzolari F, Misso C, Avenia N As the prevalence of breast cancer has increased over recent years many cases with unusual presentation are emerging. This review attempts to identify different types of primary malignancies that can affect the breast. A five years review was undertaken at the Breast Unit of Azienda Ospedaliera "Santa Maria", Terni (Italy). All cases of breast malignancy admitted to the Breast Unit between 2001 and 2005 were reviewed: 750 patients were diagnosed with malignant breast disease. Primary breast Lymphoma (was found only in two cases accounting for an incidence of 0,26%. The pre-operative diagnosis was infiltrating carcinoma in both cases and the patients were treated with surgery and systemic chemotherapy; currently they are disease- free. PMID: 18507958 [PubMed - indexed for MEDLINE] ...

Source: www.ncbi.nlm.nih.gov --- 7 days ago
Related Articles PRMT5 Suppresses the Transcription of the RB Family of Tumor Suppressors in Leukemia and Lymphoma Cells. Mol Cell Biol. 2008 Aug 11; Authors: Wang L, Pal S, Sif S Proper epigenetic modification of chromatin by protein arginine methyltransferases (PRMTs) is crucial for normal cell growth and health. The hSWI/SNF-associated PRMT5 is involved in transcriptional repression of target genes by directly methylating H3R8 and H4R3. To further understand the impact of PRMT5-mediated histone methylation on cancer, we analyzed its expression in normal and transformed human B lymphocytes. Our findings reveal that PRMT5 protein levels are enhanced in various human lymphoid cancer cells including transformed chronic lymphocytic leukemia (B-CLL) cell lines. PRMT5 overexpression is caused by altered expression of the PRMT5-specific miRNAs 19a, 25, 32, 92, 92b and 96, and results in increased global symmetric methylation of H3R8 and H4R3. Evaluation of both epigenetic marks at PRMT5 target genes such as RB1 (p105), RBL1 (p107) and RBL2 (p130) showed that promoter H3R8 and H4R3 are hypermethylated, which in turn triggers pocket protein transcriptional repression. Furthermore, reducing PRMT5 expression in WaC3CD5 B-CLL cells abolishes H3R8 and H4R3 hypermethylation, restores RBL2 expression, and inhibits cancer cell proliferation. These results indicate that PRMT5 overexpression epigenetically alters transcription of key tumor suppressor ...

Source: www.ncbi.nlm.nih.gov --- 18 days ago
Related Articles Primary tracheal Lymphoma causing respiratory failure. J Thorac Oncol. 2008 Aug;3(8):929-30 Authors: Tan DS, Eng PC, Thye LS, Tao M Lymphomatous involvement of the airway causing stridor is a rare but frightening presentation of an eminently treatable condition. We describe a 24-year-old woman with tracheal non-Hodgkin Lymphoma who was initially diagnosed with asthma, but subsequently presented with near-fatal acute upper airway obstruction because of a tracheal Anaplastic Lymphoma Kinase (ALK)+ anaplastic T-cell Lymphoma. The obstructing tumor was extricated by means of rigid bronchoscopy. After six cycles of Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone chemotherapy, the patient went into complete clinical remission. A high index of suspicion in patients with dyspnoea and wheeze unresponsive to bronchodilators is crucial in early diagnosis of tracheal tumors. PMID: 18670314 [PubMed - in process] ...

Source: www.ncbi.nlm.nih.gov --- 11 days ago
Related Articles Posterior fossa Lymphoma with initial vertigo presentation. Eur Arch Otorhinolaryngol. 2008 Aug 8; Authors: Chang RH, Young YH This study retrospectively reviewed our experience in the diagnosis of six patients with posterior fossa Lymphoma during the past decade. Initial manifestation included vertigo in all patients (100%) and ataxia in 4 (67%), with a mean duration of 40 days. Audiometry revealed sensorineural hearing loss in five patients (83%). Gaze-evoked nystagmus was also noted in five patients (83%). Electronystagmography (ENG) showed multiple central signs, e.g., abnormal eye tracking test, abnormal optokinetic nystagmus test, abnormal caloric and/or visual suppression tests. MR imaging demonstrated single or multiple or diffuse enhanced mass lesions in the cerebellum and/or brainstem. Two patients received lumbar puncture for cytological examination of cerebrospinal fluid (CSF) which disclosed Lymphoma cells, while the other four patients underwent craniotomy for tissue proof, and the histopathological study confirmed as Lymphoma. Then, all patients underwent irradiation coupled with chemotherapy. At the close of this study, three patients died, two were lost and one was alive. Although rare, aggressive posterior fossa Lymphoma should be kept in mind when seeing a patient with persistent vertigo and ataxia accompanied by multiple central signs in ENG examination. An MRI scan followed by CSF cytological examin ...

Source: www.moreover.com --- 5 days ago
The gene Rheb causes cancer and contributes to the spread of the disease, according to two recent independent studies. ...

Source: www.moreover.com --- 3 days ago
(NewsRx.com) -- Fresh data on Lymphoma are presented in the report 'Primary gastric mucosa associated lymphoid tissue Lymphoma: clinical data predicted treatment outcome. ...

Source: www.ncbi.nlm.nih.gov --- 8 days ago
Related Articles Targeting Bcl-2 family proteins modulates the sensitivity of B-cell Lymphoma to Rituximab-induced apoptosis. Blood. 2008 Aug 8; Authors: Stolz C, Hess G, Hahnel PS, Grabellus F, Hoffarth S, Schmid KW, Schuler M The chimeric monoclonal antibody Rituximab is standard of care for patients suffering from B-cell Non-Hodgkin's Lymphoma (B-NHL). Rituximab mediates complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) of CD20-positive human B cells. In addition, Rituximab sensitizes B-NHL cells to cytotoxic chemotherapy, and has direct apoptotic and antiproliferative effects. While expression of the CD20 antigen is a natural prerequisite for Rituximab sensitivity, cell-autonomous factors determining the response of B-NHL to Rituximab are less defined. To this end we have studied Rituximab-induced apoptosis in human B-NHL models. We find that Rituximab directly triggers apoptosis via the mitochondrial pathway of caspase activation. Expression of anti-apoptotic Bcl-xL confers resistance against Rituximab-induced apoptosis in vitro, and Rituximab treatment of xenografted B-NHL in vivo. B-NHL cells insensitive to Rituximab-induced apoptosis exhibit increased endogenous expression of multiple anti-apoptotic Bcl-2 family proteins, or activation of phosphatidylinositol-3-kinase (PI3K) signaling resulting in upregulation of Mcl-1. The former resistance pattern is overcome by treatment with the BH ...

Source: www.ncbi.nlm.nih.gov --- 10 days ago
Related Articles Follicular Lymphoma of the Duodenum: A Clinicopathologic Analysis of 26 Cases. Jpn J Clin Oncol. 2008 Aug 7; Authors: Sentani K, Maeshima AM, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y OBJECTIVE: Follicular lymphomas (FLs) occur commonly in the lymph nodes, and duodenal FL (DFL) is reported to be rare. METHODS: We analysed the clinical, morphological, immunohistochemical and genetic features of 26 cases of DFL. Primary DFLs and systemic FLs that involved the duodenum at any point during the clinical course were included in the analysis. RESULTS: Typically, primary DFLs (14 cases) were found incidentally at routine medical check-ups, whereas involvement of the duodenum by systemic FLs (12 cases) was found through staging procedures. All cases involved the second portion of the duodenum. Helicobacter pylori infection was common (71%). In all cases, the histologic grade was low (either grade 1 or 2), and CD20, CD10 and Bcl-2 were positive by immunohistochemistry. Immunoglobulin heavy chain gene (IGH) and bcl-2 gene (BCL2) fusion was frequently shown by fluorescence in situ hybridization (FISH) analysis: nine of 12 cases (75%) of primary DFL and 10 of 12 cases (83%) of systemic DFL were positive. Treatment regimens employed were rituximab (R) plus chemotherapy (10), R (6), chemotherapy (3), irradiation (3) and the other three patients were subjected to observation. After a median follow-up ...

Source: www.ncbi.nlm.nih.gov --- 18 days ago
Related Articles Hypoxia inducible factor-alpha activation in Lymphoma and relationship to the thioredoxin family. Br J Haematol. 2008 May;141(5):676-80 Authors: Evens AM, Schumacker PT, Helenowski IB, Singh AT, Dokic D, Keswani A, Kordeluk E, Raji A, Winter JN, Jovanovic BD, Holmgren A, Nelson BP, Gordon LI Hypoxia inducible factors (HIFs) activate oncogenic pathways, while thioredoxins (Trx), including Trx1 and Trx reductases-1 and -2 (TrxR1 and TrxR2), promote HIF-alpha stabilization. In immunoblotting studies in Lymphoma cell lines we found that Raji and SUDHL4 cells exhibited normoxic HIF-2alpha protein stabilization. Five cell lines showed increased TrxR1 expression, while only Namalwa, HF1 and SUDHL4 had Trx1 and TrxR2 activation. Tissue microarrays in diffuse large B-cell Lymphoma (DLBCL) and follicular Lymphoma (FL) identified different HIF expression among histological subgroups (e.g. 44% DLBCL vs. 11% of FL cases with moderate-to-high expression of HIF-1alpha and HIF-2alpha, P = 0.0017). These data demonstrate that HIF and the thioredoxin family are abnormally activated in Lymphoma. PMID: 18422776 [PubMed - indexed for MEDLINE] ...

Source: www.ncbi.nlm.nih.gov --- 7 days ago
Related Articles Impaired B-cell reconstitution in Lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab? Bone Marrow Transplant. 2008 Aug 11; Authors: Buser A, Stern M, Arber C, Medinger M, Halter J, Rovo A, Favre G, Lohri A, Tichelli A, Gratwohl A Allogeneic hematopoietic SCT (HSCT) is increasingly considered an option in refractory or relapsing Lymphoma. Today, most patients with B-cell Lymphoma are treated with the monoclonal anti-CD20 antibody rituximab before HSCT. We hypothesized that prior therapy with rituximab might alter immune reconstitution after allogeneic transplantation due to in vivo depletion of B cells at the time of graft infusion. We studied B-cell immune reconstitution in 12 patients with Lymphoma receiving rituximab 1-12 months before HSCT. Compared to an age- and sex-matched population of patients transplanted for myeloid malignancies, Lymphoma patients with rituximab pretreatment showed significantly reduced B-cell counts at time of HSCT at +3, +6 and +12 months; B-cell counts reached values comparable to controls only 24 months after HSCT. In parallel, levels of immunoglobulins were markedly reduced for up to 2 years post transplant in patients with prior rituximab treatment. Two patients suffered from severe late bacterial infections to which the impaired humoral immunity may have contributed. In contrast, T- and NK-cell reconstitution was not different compared to control pat ...

Source: www.ncbi.nlm.nih.gov --- 7 days ago
Related Articles Recent therapeutic advances in hematological malignancies: the role of targeted therapies in Lymphoma. Ann Oncol. 2008 Jul;19 Suppl 5:v63-7 Authors: Schmitz N PMID: 18611903 [PubMed - indexed for MEDLINE] ...

Source: www.ncbi.nlm.nih.gov --- 10 days ago
Related Articles AIDS-related primary central nervous system Lymphoma: a Norwegian national survey 1989-2003. BMC Cancer. 2008 Aug 6;8(1):225 Authors: Haldorsen IS, Krakenes J, Goplen AK, Dunlop O, Mella O, Espeland A ABSTRACT: BACKGROUND: Primary central nervous system Lymphoma (PCNSL) is a frequent complication in acquired immunodeficiency syndrome (AIDS). The objective of this survey was to investigate incidence, clinical features, radiological findings, histologic diagnosis, treatment and outcome for all patients with histologically verified AIDS-related PCNSL diagnosed in Norway in 1989-2003. METHODS: We identified the patients by chart review of all cases recorded as PCNSL in The Norwegian Cancer Registry (by law recording all cases of cancer in Norway) and all cases recorded as AIDS-related PCNSL in the autopsy registry at a hospital having 67% autopsy rate and treating 59% of AIDS patients in Norway, from 1989 to 2003. Histologic material and radiological images were reviewed. We used person-time techniques to calculate incidence rates of PCNSL among AIDS patients based on recordings on AIDS at the Norwegian Surveillance System for Communicable Diseases (by law recording all cases of AIDS in Norway). RESULTS: Twenty-nine patients had histologically confirmed, newly diagnosed AIDS-related PCNSL in Norway from 1989-2003. Only 2 patients had this diagnosis established while alive. AIDS patients had 5.5% lifetime risk of PCNSL. The ...

Source: www.ncbi.nlm.nih.gov --- 13 days ago
IL-4 protein expression and basal activation of Erk in vivo in follicular Lymphoma. Blood. 2008 Aug 5; Authors: Calvo KR, Dabir B, Kovach A, Devor C, Bandle R, Bond A, Shih JH, Jaffe ES Follicular Lymphoma (FL) is characterized by constitutive expression of Bcl-2 as a consequence of t(14;18). Evidence suggests factors in the lymph node microenvironment, related to intratumoral T-cells, macrophages, and dendritic cells, play a role in the disease process. We generated proteomic cytokine profiles of FL (N=50) and follicular hyperplasia (FH; N=23). Ten cytokines were assayed using ultrasensitive multiplex elisas: IL-1beta, IL-2, IL-4, IL-5, IL-8, IL-10, IL-13, IL-12p70, TNF-alpha, and INF-gamma. Each cytokine showed overall lower protein concentrations in FL, with the exception of IL-4, which was nearly 5 times higher in FL than FH (p= 0.0054). Using reverse-phase protein microarrays (RPMA), we evaluated the activation state of several intracellular signaling proteins downstream of cytokine receptors. Basal Erk phosphorylation was approximately 4 times greater in FL than FH (p < 0.0001) with similar findings for Mek; Stat-6 showed weak basal phosphorylation that was approximately twice as high in FL than in FH (p = 0.012). In conclusion, the FL microenvironment contains increased levels of IL-4, with prominent tumor basal phosphorylation of Erk. These findings suggest IL-4, Erk, and possibly Stat-6 may play a role in the biology of FL and ...

Source: brewersfandemonium.yuku.com --- 9 days ago
Just curious as to whether or not any of the posters on this board knows of anyone that has had it, or has it now. I'm wondering because I very recently had a biopsy done and I'm currently awaiting the results. Was/is the treatment particularly hard on your body? What kind was it specifically? I'm not really down about it persay, just looking for real accounts of what has happened to people, and not just the "statistics" that I can look up on the internet, or that I get... ...

Source: www.voanews.com --- 6 days ago
Scientists use tobacco plants to grow personalized vaccines for Lymphoma patients ...

Source: www.prnewswire.com --- 5 days ago
...

Source: www.medicinenet.com --- 5 days ago
Title: New Lymphoma Drug Shows Promise Category: Health News Created: 8/15/2008 2:00:00 AM Last Editorial Review: 8/15/2008 ...

Source: www.drugs.com --- 6 days ago
First T cell engaging antibody (BiTE) showing clinical benefit in cancer patients; Blinatumomab enables patients own T cells to recognize and attack cancer cells BETHESDA, Md., August 14, 2008 /PRNewswire-FirstCall/ -- Micromet, Inc. , a... ...

Source: www.medicalnewstoday.com --- 19 days ago
As part of its ongoing effort to find a cure for Lymphoma, the Lymphoma Research Foundation (LRF) proudly announces the 2008 Research Grant Recipients of its Post-Doctoral Fellowships and Clinical Investigator Career Development Awards, LRF's two cornerstone research programs. The two-year Post-Doctoral Fellowships help attract the nation's best scientific talent to careers in Lymphoma and allows them to pursue promising research projects under the guidance of a mentor. ...

Source: www.medicalnewstoday.com --- 5 days ago
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced publication of a Phase 1 clinical study(1) on its BiTE(R) antibody blinatumomab (MT103/MEDI-538) in this week's issue of Science. The article is available at http://www.sciencemag.org. ...